Micronized Lutein-Zeaxanthin Composition for Low Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low bioavailability and high oxidizability of natural xanthophylls, such as lutein and zeaxanthin, limit their effective utilization in nutraceutical products due to physicochemical and physiological barriers in the gastrointestinal tract, including low solubility, enzymatic transformation, and membrane transport issues.
Innovation Solution
A xanthophyll composition comprising selective trans-R,R lutein and trans-R,R zeaxanthin, prepared from two different plant sources, is enhanced by a micronization process to achieve a specific particle size, combined with bio-enhancing agents, solubility enhancers, and antioxidants, resulting in improved bioavailability and formulation into various dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural xanthophylls are used in nutraceutical products, then health benefits are provided, but bioavailability is low due to physicochemical and physiological barriers in the gastrointestinal tract
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of xanthophylls through micronization (reducing particle size to 0.1-10 microns), esterification (converting to ester forms), and encapsulation. These parameter changes enhance solubility, protect from enzymatic degradation, and improve membrane permeability, thereby resolving the bioavailability issue while maintaining health benefits
Solution Approach 2:
The patent uses intermediary substances such as phospholipids, cholesterol, and specific carriers (e.g., beta-cyclodextrin, micelles) to facilitate the absorption of xanthophylls. These intermediaries act as mediators that bridge the gap between the xanthophyll molecules and the gastrointestinal absorption mechanisms, overcoming the low bioavailability barrier
2Reliability
If xanthophyll composition is formulated with bioavailability enhancers and solubility enhancers, then bioavailability is improved 1.5 to 4-fold, but formulation complexity increases
Solution Approach 1:
The patent merges multiple functional components into integrated formulation systems. For example, it combines micronized xanthophylls with phospholipid coatings, encapsulates them in specific carriers, and formulates them as oil suspensions or beadlets. This merging approach achieves synergistic bioavailability enhancement (1.5 to 4-fold improvement) while managing formulation complexity through systematic integration rather than separate additive components
3Manufacturing precision
If xanthophylls are processed through micronization and purification processes, then selective isomers are obtained with high purity, but manufacturing complexity increases
Solution Approach 1:
The patent applies extraction principles through selective purification processes that isolate and concentrate specific xanthophyll isomers (trans-R,R lutein and trans-R,R zeaxanthin) from plant sources. Methods include chromatographic separation, crystallization, and selective esterification, which extract the desired isomers while removing unwanted stereoisomers, achieving high purity (>80%) and isomer selectivity through systematic separation processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition exhibits enhanced bioavailability, with a 1.5 to 4-fold improvement compared to reference formulations, making it suitable for human consumption in eye and brain health applications, and is free from R,S and S,S zeaxanthin isomers.
Implementation Method 1
The bioavailability of these agents can be improved by specifically designing the compositions that control their release, solubilization, transport, metabolism, and absorption within the gastrointestinal tract. Various approaches have been used to combat these problems of low bioavailability of the macular nutrients for their use in the form of nutraceutical products for human or veterinary use but there is strong felt need to improve the bioavailability.
Implementation Method 2
The oral bioavailability of many xanthophyll nutrients is limited due to physicochemical and physiological processes such as low solubility in gastrointestinal fluids
Implementation Method 3
The beneficial health effects of natural xanthophylls and their antioxidant nature are well documented throughout scientific literature. The only hindrance to the effective utilization of these properties by the body is the low bioavailability and highly oxidizable nature of these nutrients.
Data Source
AI summary
The present invention relates to a xanthophyll composition comprising selective isomers of trans-R,R lutein and trans-R,R zeaxanthin in preferred particle size and pharmaceutically and/or nutraceutically acceptable excipients such as carriers, solubility enhancers, bioavailability enhancing agents, antioxidants and optionally flavoring agents with selective ratio which exerts enhanced bioavailability. The xanthophyll composition at least 80% of total xanthophyll comprised of at least 65% by weight of trans-R,R lutein and at least 10% by weight of trans-R,R zeaxanthin, which is prepared combinedly from marigold and paprika oleoresins with definite proportion to produce the preferred ratio of trans-R,R lutein and trans-R,R zeaxanthin.